Alamar Biosciences, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ALMR in the last 7 days.
No SEC Form 4 filings for $ALMR in the last 30 days.
See all $ALMR insider activity →Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.
Investing.com reports major U.S. stock movers, led by FRMI up 22.2% on an AI campus lease and potential revenue expansion, ALMR up 28.3% after launching an immune profiling panel, and Hertz up 24.5% on index removal and heavy options activity. Other gainers include Septerna, Rapid7, Kopin, and NextNav, with catalysts tied to AI, biotech, and earnings.
Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.
Recent ALMR coverage spans technology, earnings and market movers.
Earnings call provides fresh operating metrics and explicit 2026 revenue guidance, shifting near-term expectations for growth and margin volatility.
Product-launch catalyst supports a bullish short-term setup.
Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.
The 8-K discloses a fresh quarterly print plus an updated full-year revenue range, which can reprice near-term growth expectations.
The launch is a product expansion that could support incremental demand from translational and drug-development labs, but it provides no financial guidance or adoption metrics.
alphai scores every news story that mentions ALMR with an AI model for sentiment and relevance, and aggregates insider trades from Alamar Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.
7 min readInvesting.com reports major U.S. stock movers, led by FRMI up 22.2% on an AI campus lease and potential revenue expansion, ALMR up 28.3% after launching an immune profiling panel, and Hertz up 24.5% on index removal and heavy options activity. Other gainers include Septerna, Rapid7, Kopin, and NextNav, with catalysts tied to AI, biotech, and earnings.
6 min readAlamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.
6 min readAlamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detectio
4 min readAlamar Biosciences (Nasdaq: ALMR) announced the launch of its NULISAseq Immune 340 Panel, expanding its NULISAseq Inflammation Panel 250 to measure about 340 immune-related proteins from a single sample. The company says the panel targets low-abundance proteins and regulatory markers, supporting translational research and drug development across cancer, cardiovascular, metabolic, autoimmune, and aging.
3 min readAlamar Biosciences (ALMR) shares rose 7.3% to a 52-week high of $28.42 after the company said its NULISA platform will be featured in more than 140 presentations at the Alzheimer’s Association International Conference, according to the company. The article notes no earnings or analyst action and contrasts weaker moves at peers like TMO and ILMN.
4 min readBiotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.
5 min readAlamar Biosciences (Nasdaq: ALMR) said it will partner with research universities to launch a national proteomics initiative for Alzheimer’s and related dementias. It will profile about 21,000 plasma samples from 10,000 ADRD participants using its NULISAseq Neuro 220 panel, including an eMTBR-Tau assay, with data linked to NACC IDs and made publicly accessible.
3 min readAlamar Biosciences (Nasdaq: ALMR) said its NULISA platform data will be featured in more than 140 poster and session presentations at the Alzheimer’s Association International Conference (AAIC) in London July 12-15. The company will host a workshop on July 14 highlighting eMTBR-Tau and BD-pTau217 assays measured on a single NULISAseq panel with 220+ proteins, and claims improved discrimination versus pTau-217 alone.
3 min readAlamar Biosciences (Nasdaq: ALMR) launched a commercial blood-based eMTBR-Tau immunoassay for Alzheimer’s disease. The assay is available in the NULISAseq Neuro 220 multiplex panel for use on Alamar’s ARGO HT instruments and as a single-plex via its Technology Access Program. Alamar plans to present related performance and clinical data at AAIC 2026.
3 min read
